Shots:

• Merck will acquire all the outstanding shares of VelosBio for $2.75B in cash. The transaction is expected to be closed by the end of 2020
• The acquisition will bolster Merck’s oncology pipeline with the addition of VelosBio’s VLS-101- which is an investigational ADC targeting ROR1 to treat hematological malignancies and solid tumors
• In Oct’2020- VelosBio has initiated P-II study to evaluate VLS-101 for the treatment of patients with solid tumors- including patients with TNBC- HR+/HER2+ BC- and NSCLC. Additionally- VelosBio is developing a preclinical pipeline of ADCs and bispecific Abs targeting ROR1 to complement VLS-101 by offering alternative methods of tumor cell killing

  Ref: PRNewswire | Image: Merck